Loading patent…
AssigneeAethlon Medical, Inc.
InventorsCharles J. Fisher, Steven P. Larosa, Rosalia De Necochea Campion, Paul Vallejos, Lee D. Arnold, Miguel Angel Pesqueira
Estimating the term…
Aspects described herein concern methods for removing subcellular nanoparticles, pathogens, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker or mediator of tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and/or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, or glycolipids, or fragments thereof from organ, tissue, or cell transplant donors, organ, tissue, or cell transplant recipients, or donor organs before, during and/or after transplantation into the recipient.
-87. (canceled)
A method for removing miRNAs from a sample, the method comprising:
A method for removing miRNAs from a subject, the method comprising:
An extracorporeal device comprising a hollow fiber cartridge comprising Galanthus nivalis agglutinin (GNA) lectin, wherein blood or plasma can flow through hollow fibers of the hollow fiber cartridge, wherein the hollow fibers of the hollow fiber cartridge comprise a pore size that excludes cellular components of the blood or plasma from contacting the lectin, such as a pore size of 20-500 nm or about 20-500 nm or 200 nm or about 200 nm, wherein the lectin is immobilized on to a solid support, and the hollow fiber cartridge comprises the lectin immobilized on the solid support, wherein the solid support preferably comprises diatomaceous earth, further comprising miR-2110, miR-320b, miR-130b-3p, and/or miR-484.
Dependencies are inferred from the claim text.